Avicanna Applauds President Trump’s Executive Order to Reclassify Cannabis & Provides Scientific Update

Core Insights - Avicanna Inc. supports President Trump's executive order to reclassify cannabis from Schedule I to Schedule III, emphasizing the importance of scientific research in the field of cannabinoid-based medicine [2][3] - The company has made significant advancements in research and development (R&D), clinical development, and medical affairs, positioning itself for future growth and innovation in cannabinoid therapies [2][6] R&D and Clinical Development - Avicanna has established a scientific platform that includes over thirty proprietary, evidence-based finished products and supports four commercial stage business pillars [5] - The company is executing a balanced clinical development strategy, with approximately 450 patients enrolled in a real-world evidence study evaluating outcomes related to pain, sleep, anxiety, and depression [6] - A Phase II randomized controlled trial for evaluating arthritic pain using Avicanna's proprietary cannabinoid formulations commenced in December 2025 [6] Medical Affairs and Education - Avicanna has expanded its engagement with healthcare professionals through educational events and initiatives, contributing to improved patient access and support programs [6] - The MyMedi.ca platform aims to enhance the medical cannabis patient journey, providing bilingual pharmacist-led support and specialty services for distinct patient groups [9] Pharmaceutical Pipeline - The company has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [9] - Active pharmaceutical ingredients are supplied by Avicanna's subsidiary, Santa Marta Golden Hemp SAS, which provides high-quality CBD, THC, and CBG for various applications [9]